Moleculin Biotech, Inc., a clinical stage pharmaceutical company, has recently announced the publication of data from its successful Phase 1 clinical trial evaluating Annamycin as a single agent treatment for relapsed or refractory Acute Myeloid Leukemia (AML). The findings of this study were published in the highly regarded British Journal of Cancer Research, after undergoing a thorough peer-review process. One of the key highlights from the study is that there was no evidence of cardiotoxicity observed in any of the subjects treated with Annamycin, even in those who exceeded the lifetime cumulative dose of anthracycline. Currently, Annamycin is being further evaluated in a Phase 1b/2 study in combination with Cytarabine for the treatment of AML.
The published manuscript includes contributions from Moleculin's European Chief Medical Officer and Senior Chief Medical Officer, as well as Polish investigators who participated in the trial. The results obtained from this trial have provided valuable insights for Moleculin's AML program and have guided their clinical development strategy for Annamycin. With these positive outcomes, the company remains optimistic about Annamycin's